Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neuroblastoma 1 Neoplasms 1 Lymphoma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 101 Etoposide 60 Carboplatin 55 Vincristine 51 Filgrastim 49 Topotecan 44 Temozolomide 44 Melphalan 44 Isotretinoin 44 Doxorubicin 44 Irinotecan 42 Cisplatin 35 3-Iodobenzylguanidine 34 Peripheral Blood Stem Cell Transplantation 31 dinutuximab 30 Granulocyte Colony-Stimulating Factor 30 Radiotherapy 29 sargramostim 28 Granulocyte-Macrophage Colony-Stimulating Factor 25 Busulfan 22 Magnetic Resonance Spectroscopy 19 aldesleukin 18 Thiotepa 18 fludarabine 17 Interleukin-2 17 humanized 3F8 anti-GD2 monoclonal antibody 16 etoposide phosphate 16 naxitamab 15 Ifosfamide 15 Biopsy 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroblastoma × Pharmaceutical Preparations × CNS × Clear all

NCT07334301 2026-01-12

BEACON2

University of Birmingham

Phase 1/2 Recruiting

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡